Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen (FORCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02739477
Recruitment Status : Terminated (End date of epidemic)
First Posted : April 15, 2016
Last Update Posted : October 18, 2018
Information provided by (Responsible Party):
Institut National de la Santé Et de la Recherche Médicale, France

Brief Summary:
This study aims to evaluate favipiravir high dose tolerance in male survivor of Ebola Virus Disease (EVD) with Ebola Virus (EBOV) RNA in semen. This is a dose escalation study with 3 cohorts of 6 patients, each dose level including 2 sentinel patients.

Condition or disease Intervention/treatment Phase
Ebola Virus Survivor Drug: Favipiravir Phase 2

Detailed Description:


  • Data suggesting persistence of EBOV in semen a few months after the end of EVD and sexual transmission of EBOV
  • Encouraging results on favipiravir efficacy to reduce mortality of EVD in JIKI trial (NCT02329054 )
  • Favipiravir trough plasma concentration in JIKI trial lower than predicted by population pharmacokinetic model, suggesting an increase of dose might be necessary to achieve a therapeutically relevant exposure.


  • Primary objective: to assess clinical and biological tolerance of high-dosed favipiravir bid for 14 days
  • Secondary objectives: to assess the activity of favipiravir on evolution of EBOV RNA and infectious loads in semen under treatment; the trough plasma and semen concentrations of favipiravir; and genetic factors associated with favipiravir pharmacokinetic.

Dose escalation scheme:

Each patient of each cohort will receive favipiravir loading doses of 4800 mg at Day 1 (2400 mg bid), following by 3600 mg (1800 mg bid) from Day 2 to 14 (cohort 1), then 3600, 4200 or 4800 mg from Day 2 to 14 (cohort 2 and 3), depending on previous cohort results.

Escalation rules are based on the number of patient undergoing treatment-related adverse events (TRAE) of grade 3 or 4 according to the Common Terminology Criteria for Adverse Events v4.03 (CTCAE), as defined by the investigator and sponsor.

Participants will attend medical visits at Day 1, Day 3, Day 7, Day 10, Day 14, Day 21 and clinical tolerance will be assessed daily by phone call from Day 1 to Day 14.

At the end of the first cohort:

  • if no TRAE, cohort 2 will be given 2400 mg bid from Day 2 to 14;
  • if 1 or 2 TRAE is observed, cohort 2 will be given 2100 mg bid from Day 2 to Day 14;
  • if 3 or more TRAE is observed, cohort 2 will be given the same dose as cohort 1.

At the end of cohort 2, same rules will be apply to cohort 3, without exceed 4800 mg of favipiravir per day.

Each cohort will include 6 patients. Each dose level will comprise 2 sentinel patients.

In their own interest, patients included in a cohort with detection of EBOV RNA in semen by RT-PCR (CT<38) at Day 21, could be included in the next cohort.

Recruitment will start among PostEbogui cohort from coast Guinea.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Tolerance and Activity Assessment of High Doses of Favipiravir in Male Survivors With Ebola Virus in the Semen
Study Start Date : April 2016
Actual Primary Completion Date : August 2016
Actual Study Completion Date : August 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Favipiravir
Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
Drug: Favipiravir

Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).

Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.

Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results.

Other Name: AVIGAN

Primary Outcome Measures :
  1. Number of patients undergoing grade 3 or 4 clinical or biological adverse events related to Favipiravir (Common Terminology Criteria for Adverse Events, CTCAE, v4.03) [ Time Frame: Day 14 ]
    Day 1 is the first day of favipiravir intake

Secondary Outcome Measures :
  1. Evolution of EBOV semen RNA and infectious loads [ Time Frame: Semen collection will be performed at least at Day 7, Day 14, Day 21 and Day 90 ]
    From Day 14 to Day 90, semen EBOV PCR will be performed every 3 weeks until their semen tests negative for virus twice by RT-PCR, with an interval of one week between tests.

  2. Plasma and semen trough concentrations of favipiravir [ Time Frame: Plasma collection at Day 3, Day7, Day 10 and Day 14. Semen collection at Day 7 and Day 14 ]
  3. Genetic variations associated with favipiravir exposition [ Time Frame: Blood collection at Day 1 will be used for further genotyping. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male survivor of biologically confirmed EVD
  • age >= 18 years
  • EBOV RT-PCR on semen with cycle threshold [Ct]<38 at Day -7 and semen aliquot available for later quantification of EBOV
  • signed informed consent

Non-Inclusion Criteria:

  • EBOV RT-PCR on blood with cycle threshold [Ct]<38 at Day -7
  • Biological abnormality higher than grade 2 according to CTCAE (v4.03) on following parameters: creatinine, ASAT, ALAT, alkaline phosphatase, total bilirubin
  • Fridericia corrected QT interval (QTc) > 450 ms
  • Concomitant use of QT/QTc interval-prolonging drugs or drugs that could cause electrolyte imbalance, such as: loop diuretics, thiazide diuretics or related
  • Previous gout attack or ongoing treatment for gout or hyperuricemia
  • Ongoing pyrazinamide treatment or other drug known to induce hyperuricemia
  • Previous hypersensitivity reaction due to nucleoside analogue
  • Symptom or biological value suggesting systemic disorder (renal, hepatic, cardio-vascular, pulmonary) or any medical condition that could interfere with results interpretation or compromise participants' health
  • Explicit refusal to comply with proper use of drug (condom use)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02739477

Layout table for location information
Conakry, Guinea
Nzérékoré, Guinea
Sponsors and Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
Layout table for investigator information
Principal Investigator: Daouda Sissoko, Doctor Inserm 897 unit, ISPED, Université de Bordeaux, Bordeaux cedex
Layout table for additonal information
Responsible Party: Institut National de la Santé Et de la Recherche Médicale, France Identifier: NCT02739477    
Other Study ID Numbers: C15-101
First Posted: April 15, 2016    Key Record Dates
Last Update Posted: October 18, 2018
Last Verified: May 2016
Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France:
Ebola Virus
Genital reservoir
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemorrhagic Fever, Ebola
Virus Diseases
Hemorrhagic Fevers, Viral
RNA Virus Infections
Filoviridae Infections
Mononegavirales Infections
Antiviral Agents
Anti-Infective Agents